期刊
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
卷 62, 期 3, 页码 264-271出版社
WILEY
DOI: 10.1111/j.1365-2125.2006.02654.x
关键词
orphan disease; orphan medicinal product; rare disease; ultra orphan disease
Orphan medicinal products (OMPs) are targeted at the diagnosis, prevention or treatment of rare diseases and have a special status in European law. This status brings incentives for pharmaceutical companies to invest in OMP development. The goal of the legislation is to encourage the development of more treatments for life-threatening rare disorders, but increased availability of OMPs raises important issues surrounding the public funding of very expensive treatments by national health services. In this article we review OMPs and the incentives for their development and discuss the challenges presented by funding these treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据